Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Completed · Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and interferon alfa in treating patients with chronic myelogenous leukemia.
Key facts
- Study ID
- NCT00002598
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 30
- Starts
- 1994-06-01
- Expected to finish
- 2004-06-01
- Last updated by the study team
- 2013-06-25
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.